U.S. Luxury Stock News

Novo Nordisk stock combines a weak three year share price record with valuation checks that still lean supportive, which raises questions about how much pessimism is already reflected in today’s price. Over the past three years the share price has declined 45.7%, which suggests investors have meaningfully reset their expectations for the business. Expectations around Novo Nordisk’s ability to grow and defend its position in the obesity treatment market can support the investment case. At the...

PepsiCo recently appointed Nidhima M., a veteran HR leader with nearly 19 years of global experience, as Senior Director of HR for India, Bangladesh and Nepal, while also preparing to release its third-quarter 2026 results and deepening its commercial partnership with autonomous trucking firm Gatik. These developments highlight PepsiCo’s growing emphasis on international leadership, technology-enabled logistics, and overseas operations as central pillars of its longer-term diversification...

Septerna, Inc. recently appointed Rajiv Patni, M.D., as Chief Medical Officer, adding a physician-scientist with more than 25 years of global biopharmaceutical leadership experience across research, development, regulatory, and medical affairs roles. His track record contributing to 10 regulatory approvals or label expansions and leadership roles at companies that were later acquired may influence how investors view Septerna’s ability to advance its pipeline and execute on clinical...

Talks over new shipping routes and mine clearance in the Strait of Hormuz are reshaping how investors think about oil flows and risk. When a chokepoint for global crude looks a little less fragile yet still uncertain, pricing, margins and capital plans for integrated energy giants can all come under review. This article walks through three large oil and gas stocks exposed to this news and how the shifting risk picture could matter for your portfolio. The three integrated giants covered below...

In August 2026, Merck & Co. and Moderna reported positive Phase 3 results from the INTerpath-001 trial, showing that individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) plus KEYTRUDA improved recurrence-free and distant metastasis-free survival versus KEYTRUDA alone in resected stage IIB–IV melanoma, with no new safety signals. This is the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer therapy, highlighting a potential...

Waste Connections stock has delivered a 33.4% total return over the last five years, yet the current valuation signals are split. The intrinsic value estimate from a Discounted Cash Flow (DCF) model points to upside relative to the market price, while earnings based multiples suggest the shares trade at a premium. The 33.4% five year return suggests Waste Connections has already created solid value for long term shareholders, so fresh buyers now need to think carefully about what is priced...

Argan stock has delivered an exceptionally strong move over the past three years, yet on the current checks it screens as expensive rather than a clear bargain. After that run, investors are now facing a share price that has pulled back recently but still carries a low overall value score and an overvalued read on market multiples. Argan has returned very roughly 10x over the past three years, which means even small changes in expectations can have a meaningful impact on what feels like a...

JD.com (NasdaqGS:JD) has drawn fresh investor attention after committing RMB 10 billion to a global robotics push by 2028, targeting homes, businesses, and public services with extensive after-sales networks and new engineering jobs. See our latest analysis for JD.com. Investors have reacted only modestly so far, with JD.com’s 7 day share price return of 1.87% and year to date share price return roughly flat. The 1 year total shareholder return is down 4.48%, suggesting momentum is still...

Earlier this month, Foot Locker announced The Crenshaw Rec by Foot Locker in Los Angeles, a community-focused retail hub co-developed with Nike, Jordan Brand and Converse, featuring exclusive local collections, programming, and neighborhood hiring initiatives. This community-led concept illustrates how Nike is tying its brands more closely to cultural influence and local engagement, particularly with younger consumers. Now we’ll examine how this community-centric retail partnership,...

Tompkins Financial recently announced a quarterly dividend of US$0.70 per share, lifting its annualized payout to US$2.80, an increase of 11.6% from the prior year and ahead of the Banks – Northeast industry yield, alongside expectations for higher earnings in its current fiscal year. This combination of sustained dividend growth and an anticipated improvement in earnings has reinforced Tompkins Financial’s income and quality-focused appeal for investors. We’ll now examine how Tompkins...

Axos Financial (AX) has drawn fresh attention after recent trading data showed the stock at $98.82 as of 25 August 2026, with performance figures available for the past week, month and past 3 months. See our latest analysis for Axos Financial. Over the past year Axos Financial has paired a strong 13.46% 90 day share price return with a 131.16% three year total shareholder return. This suggests recent momentum has added to an already sizeable long term payoff for investors tracking both price...

Monolithic Power Systems (MPWR) is back in focus after reporting strong growth in its Enterprise Data segment, which highlights rising demand for its power management solutions across data centers, AI workloads, and server infrastructure. See our latest analysis for Monolithic Power Systems. At a share price of $1,304.15, Monolithic Power Systems has seen its short term share price return weaken, with the 90 day share price return down 19.51%, even though the year to date share price return...

Kennametal (KMT) has added Dawne S. Hickton and Richard J. Harshman to its Board of Directors, a governance event that gives investors fresh context for assessing the stock after recent share price moves. See our latest analysis for Kennametal. The new board appointments arrive after a mixed stretch for Kennametal, with the share price falling 16.9% over the past month and 15.8% over the past quarter, even as the 1 year total shareholder return is 39.9%, which suggests longer term momentum...

Monte Rosa Therapeutics (GLUE) dosed the first patient in its MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide for AR mutation-positive metastatic castration-resistant prostate cancer, building on earlier combination data with enzalutamide. See our latest analysis for Monte Rosa Therapeutics. The MRT-2359 update comes after a sharp 36.08% decline in the 30-day share price return and a 24.05% decline over 90 days, even as the 1-year total shareholder return of 211.78% and 3-year total...

JPMorgan Chase (NYSE:JPM) and several large US banks have committed billions of dollars to new affordable housing efforts through JPMorgan’s American Dream Initiative. The housing push targets the ongoing national shortage of affordable homes and responds to changing conditions in the US mortgage market. JPMorgan and Morgan Stanley are also facing fresh shareholder lawsuits that question their advisory roles in certain private equity buyouts. The new commitments and legal actions raise fresh...

After almost doubling over the past five years, MetroCity Bankshares now faces a more nuanced valuation picture, with the Excess Returns intrinsic value estimate suggesting the stock trades at a sizeable discount even as market multiples look broadly in line. MetroCity Bankshares has returned 99.1% over five years, which puts current pricing under the spotlight for anyone considering a fresh entry or adding to an existing position. The key support for the valuation can come from the bank's...

Personalis, Inc. has received a new task order under its contract with the U.S. Department of Veterans Affairs’ Million Veteran Program, effective 30 September 2026 and valued at up to US$18.3 million, bringing the cumulative value of its VA MVP task orders to approximately US$243.3 million. This additional VA MVP work highlights Personalis’ growing role as a key genomics partner to a major federal healthcare program focused on large-scale precision medicine research. We’ll now examine how...

With Canada and the US trading tariff blows on about $40b of goods, cross border supply chains face real friction and some companies may find new demand at home. This kind of disruption often rewards investors who identify which businesses are exposed to the news for the right reasons. The article examines three stocks from our North American onshoring screener that may be positioned to benefit from this shift. The three stocks below are just a starting sample, since the full screen surfaced...

Chewy (CHWY) is back in focus after a 2% gain in its latest session, which came despite a mixed broader market as investors look ahead to the company’s earnings report on September 9, 2026. See our latest analysis for Chewy. Chewy’s recent 7.16% 7 day share price return and 18.36% 30 day share price return suggest short term momentum is improving, although the 39.41% decline in 1 year total shareholder return shows longer term performance is still weak. If you are looking beyond Chewy to see...

A federal court has allowed a securities fraud class action against Symbotic and several executives to proceed, after finding that certain past statements about accelerating deployment of its warehouse automation systems were sufficiently challenged to merit further litigation. This ruling raises fresh questions about the reliability of prior management commentary on deployment progress and operational execution, which could influence how investors interpret Symbotic’s growth story and...

On 13 August 2026, Zoetis Inc. announced that its Simparica Trio chewable received U.S. FDA Emergency Use Authorization to treat life-threatening New World screwworm infestations in dogs and puppies. This temporary authorization underscores Zoetis’s capacity to rapidly repurpose an established parasiticide franchise for emerging threats in the companion-animal market. We’ll now explore how this emergency expansion of Simparica Trio’s use could influence Zoetis’s broader investment narrative...

General Mills (GIS) is leaning on its Betty Crocker brand for a fresh marketing push, rolling out new packaging across baking aisles and launching limited-edition Betty Ate cake-slice handbags ahead of peak baking and fashion seasons. See our latest analysis for General Mills. For investors, the latest Betty Crocker push comes as General Mills trades at US$39.78, with a 30 day share price return of 10.41% and a 90 day gain of 18.22%, but a 1 year total shareholder return that declined 14.20%...

Digital Turbine (APPS) has drawn fresh attention after expanding its alternative app distribution push through new carrier partnerships, including Orange, while regulatory shifts such as the Epic Google case and EU rulings continue to reshape app store economics. See our latest analysis for Digital Turbine. Digital Turbine’s latest moves around alternative app distribution come after a strong run in the stock, with a 30 day share price return of 28.17% and a 1 year total shareholder return of...

Earlier in August 2026, Lowey Dannenberg filed the first consumer class action against Hims & Hers Health following an FTC-led civil enforcement complaint alleging misleading “free consultation” offers, problematic subscription practices, and improper sharing of sensitive health data with advertisers. On top of these legal and regulatory actions, an advertising review body has pushed Hims & Hers to alter several product claims, sharpening investor focus on the company’s compliance, marketing...